Philippe P. Calais

Philippe P. Calais is recorded as Board Member at Transcode Therapeutics, Inc. (RNAZ) since January 1, 2018 and CEO at Transcode Therapeutics, Inc. (RNAZ). The newest filing on record that lists Philippe P. Calais as CEO and Board Member at Transcode Therapeutics, Inc. (RNAZ) is dated June 2, 2026. The proxy statement of Transcode Therapeutics, Inc. reports total compensation of $373,808 for Philippe P. Calais in fiscal 2025, including a base salary of $123,808. Disclosed compensation is on record for 2 fiscal years. Transcode Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Transcode Therapeutics, Inc. includes Philippe Calais (CEO), Thomas A. Fitzgerald (CEO and CFO), John Tattory (CFO) and 6 others.